Barclays analyst James Gordon upgraded Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) from Underweight to Equalweight with a price target of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE